Showing 1 - 10 of 57
Our latest thinking into the insurance impacts arising from the ongoing crisis is offered against the Prime Minister, Boris Johnson, having confirmed that the five tests which must be satisfied before lockdown can be adjusted have been met.
As the race to find treatments and ultimately a vaccine for COVID-19 intensifies, governments and policymakers are under increased pressure to consider unprecedented methods to address the urgency of the pandemic as quickly as possible.
This report looks at who currently bears the cost of funding personal care for those with catastrophic injuries, and the need to better manage these costs in future.
Our latest thinking into the insurance impacts arising from the ongoing crisis is offered against a positive step in the UK exit strategy. Abbott and Roche have now both been approved to provide COVID-19 antibody tests in the UK.
As the race to find treatments and ultimately a vaccine for COVID-19 intensifies, questions are being raised regarding the mechanisms available to governments and policymakers that may unlock potential solutions.
Kennedys celebrates office anniversary by launching Sheffield healthcare practice with new partner hire
We are pleased to announce that we have hired healthcare partner, Tom Armstrong, to head up a new healthcare team based in our Sheffield office, which opened in 2010. Tom, who joins from Browne Jacobson, will lead a team in Sheffield able to defend clinical negligence claims against GPs, NHS Trusts and private healthcare providers. Tom will be working closely with our healthcare lawyers in Birmingham, Cambridge and London.
Financial Conduct Authority has announced it intends to ask the courts to rule on whether a ‘representative sample of the most frequently used’ BI policy wording provide cover for COVID-19 related losses.
With the UK Government calling on organisations from a variety of industries to help solve the country’s COVID-19 ventilator shortage, we explore what organisations should consider when considering manufacturing ventilators.
We continue to assess the impact of the COVID-19 pandemic on the life sciences industry and in this update we consider the EU response to supply chain disruption, vaccine R&D and antibody testing kits.